The buyback covers up to 54.23 lakh fully paid-up equity shares of face value ₹1 each at a price of ₹1,475 per share, payable in cash. The company said the Letter of Offer dated April 21, 2026, has been emailed to eligible shareholders holding shares as on the record date of April 17, 2026.
The buyback will open on April 23, 2026 and close on April 29, 2026. The last date for receipt of completed tender forms and related documents by the registrar is April 29, 2026.
Also Read: Aurobindo Pharma gets FDA nod for cough medicine dextromethorphan ER
Settlement of bids by the clearing corporation/BSE is scheduled for May 7, 2026. The company had earlier submitted the public announcement for the buyback on April 8, 2026.
Buyback History
This is Aurobindo Pharma’s first share buyback in nearly two years. Back in August 2024, the company had announced the repurchase of 51.36 lakh equity shares at a price of ₹1,460 apiece. The drugmaker had spent ₹750 crore for this buyback, which was also carried out via the tender offer route.
Shares of Aurobindo Pharma Ltd ended at ₹1,387.05, down by ₹19.35, or 1.41%, on the BSE.
Also Read: Aurobindo Pharma arm expands MSD pact, to invest $150-175 million in new facility
(Edited by : Jomy Jos Pullokaran)
First Published: Apr 21, 2026 4:45 PM IST
